- CH₣46.96bn
- CH₣50.68bn
- CH₣6.53bn
Lonza's half-year core profit tops market expectations (updated)
Swiss stocks - Factors to watch on July 23
Brief: Lonza - H1 Sales CHF 3.6 Billion, CER Growth Of 19.0%
Lonza's half-year core profit tops market expectations
Brief: Lonza Expects Sales In H2 2025 To Be Higher Than In H1
Brief: Lonza H1 Sales CHF 3,600 Million Vs. IBES Estimate CHF 3,464 Million
Table: Swiss trade surplus at CHF 5.79 bln in June
Europe Research Roundup: Accesso Technology Group, BAE Systems, Volex
Table: Swiss trade surplus at CHF 3.831 bln in May
Table: Swiss trade surplus at CHF 6.358 bln in April
Swiss stocks - Factors to watch on May 13
Swiss stocks - Factors to watch on May 9
Brief: Lonza Posts Strong CDMO Performance In Q1 2025
RCS - Enviro Tech chemical - Introducing NUGEN(R) HLD-CD by Arxada
Table: Swiss trade surplus at CHF 6.350 bln in March
ArgenX rises on FDA approval for self-administered Vyvgart syringe
Lonza assures analysts of its tariff resilience, shares rise
Brief: Ethris And Lonza Collaborate To Develop Spray-Dried Mrna Vaccines
European pharma stocks fall ahead of Trump's 'Liberation Day'